title: [Follow up of Crohn's disease under therapy with hydro-MRI].
abstract: OBJECTIVE
  Evaluation of typical MRI-findings in patients with Crohn's disease receiving therapy. Correlation with the course of disease.
  
  
  METHODS
  81 follow-up MRI-studies in 25 patients conducted within a period of 3 weeks to 4 years were evaluated retrospectively. Therapy consisted in various combinations of antibiotics and immunosuppressive agents and if necessary operation. The findings of the MRI-studies were correlated with clinical data (e.g.operation of Crohn's complications) and the subjective perception during therapy.
  
  
  RESULTS
  The morphological substrate of Crohn's disease in the Hydro-MRI images is reliably detected. Especially in a delineation of extraluminal changes MRI is superior to endoscopy and enteroclysis. Independent from clinical symptoms short- and mid-term follow-up showed inflammatory changes of the intestinal wall in all 25 patients. In 24/81 studies there was persistence or even progression of Crohn's disease in the MRI-studies, although patients were free of symptoms by the time of image acquisition.
  
  
  CONCLUSIONS
  Hydro-MRI is a modality for the evaluation of inflammatory changes in patients with Crohn's disease. Independent from clinical symptoms persistence of Crohn's disease is detectable.
authors.affiliation: Abt.Radiodiagnostik, Radiologische Uniklinik Heidelberg.
authors.forename: M
authors.initials: M
authors.lastname: Ganten
authors.forename: J
authors.initials: J
authors.lastname: Encke
authors.forename: P
authors.initials: P
authors.lastname: Flosdorff
authors.forename: B
authors.initials: B
authors.lastname: Grüber-Hoffmann
authors.forename: G
authors.initials: G
authors.lastname: Erb
authors.forename: J
authors.initials: J
authors.lastname: Hansmann
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003424:Crohn Disease / Q000175:diagnosis* / Q000188:drug therapy*; D003524:Cyclosporins / Q000627:therapeutic use; D004733:Enema; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D003524:Cyclosporins; D007166:Immunosuppressive Agents; D013449:Sulfonamides; D008795:Metronidazole; D001379:Azathioprine; D008727:Methotrexate